Merck (MRK) Cash & Equivalents (2009 - 2026)

Merck has disclosed Cash & Equivalents across 18 years of filings, most recently posting $5.3 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 38.27% year-over-year to $5.3 billion; the TTM figure through Mar 2026 stood at $5.3 billion (down 38.27% YoY), while the FY2025 annual figure was $14.6 billion, up 9.99% from the prior year.
• Cash & Equivalents fell to $5.3 billion in Q1 2026, from $14.6 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for MRK reached as high as $18.2 billion in Q3 2025 and fell as low as $5.3 billion in Q1 2026.
• The 5-year median for Cash & Equivalents is $9.7 billion (2022), against an average of $10.1 billion.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 46.11% — and 2024, when it soared 99.72%.
• A 5-year view of Cash & Equivalents shows it stood at $12.7 billion in 2022, then tumbled by 46.11% to $6.8 billion in 2023, then surged by 93.57% to $13.2 billion in 2024, then grew by 9.99% to $14.6 billion in 2025, then tumbled by 63.43% to $5.3 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $5.3 billion, $14.6 billion, and $18.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.